BNP Paribas Financial Markets’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-91,516
| Closed | -$169K | – | 4064 |
|
|
2023
Q1 | $169K | Buy |
91,516
+1,257
| +1% | +$1.56K | ﹤0.01% | 3203 |
|
|
2022
Q4 | $100K | Buy |
90,259
+70,383
| +354% | +$100K | ﹤0.01% | 3257 |
|
|
2022
Q3 | $46.5K | Buy |
19,876
+10,761
| +118% | +$38.1K | ﹤0.01% | 3994 |
|
|
2022
Q2 | $27.6K | Buy |
9,115
+4,623
| +103% | +$22.5K | ﹤0.01% | 3664 |
|
|
2022
Q1 | $30.5K | Sell |
4,492
-8,785
| -66% | -$62.6K | ﹤0.01% | 3663 |
|
|
2021
Q4 | $111K | Buy |
13,277
+3,871
| +41% | +$31.9K | ﹤0.01% | 3564 |
|
|
2021
Q3 | $69.9K | Buy |
9,406
+6,103
| +185% | +$37.8K | ﹤0.01% | 3416 |
|
|
2021
Q2 | $22.5K | Sell |
3,303
-4,524
| -58% | -$37.6K | ﹤0.01% | 3504 |
|
|
2021
Q1 | $80.4K | Buy |
7,827
+4,698
| +150% | +$51.5K | ﹤0.01% | 3449 |
|
|
2020
Q4 | $21.9K | Sell |
3,129
-608
| -16% | -$4.73K | ﹤0.01% | 3830 |
|
|
2020
Q3 | $30.5K | Buy |
3,737
+2,863
| +328% | +$17.8K | ﹤0.01% | 3676 |
|
|
2020
Q2 | $6.03K | Sell |
874
-4,187
| -83% | -$22.6K | ﹤0.01% | 3927 |
|
|
2020
Q1 | $24K | Buy |
5,061
+1,161
| +30% | +$6.68K | ﹤0.01% | 3857 |
|
|
2019
Q4 | $34K | Buy |
3,900
+1,311
| +51% | +$7.09K | ﹤0.01% | 3841 |
|
|
2019
Q3 | $8.62K | Sell |
2,589
-5
| -0.2% | -$20 | ﹤0.01% | 4181 |
|
|
2019
Q2 | $12.8K | Sell |
2,594
-744
| -22% | -$3.95K | ﹤0.01% | 4045 |
|
|
2019
Q1 | $20.7K | Buy |
3,338
+2,940
| +739% | +$14.2K | ﹤0.01% | 3900 |
|
|
2018
Q4 | $1.34K | Sell |
398
-237
| -37% | -$1.11K | ﹤0.01% | 3881 |
|
|
2018
Q3 | $4.13K | Sell |
635
-394
| -38% | -$2.93K | ﹤0.01% | 4129 |
|
|
2018
Q2 | $7.88K | Sell |
1,029
-2,108
| -67% | -$30.4K | ﹤0.01% | 3896 |
|
|
2018
Q1 | $70.1K | Buy |
3,137
+377
| +14% | +$8.37K | ﹤0.01% | 3375 |
|
|
2017
Q4 | $35.2K | Buy |
2,760
+2,131
| +339% | +$31.3K | ﹤0.01% | 3821 |
|
|
2017
Q3 | $9.8K | Sell |
629
-37
| -6% | -$523 | ﹤0.01% | 3877 |
|
|
2017
Q2 | $9.34K | Buy |
+666
| New | +$14.3K | ﹤0.01% | 3957 |
|
Other funds holding JNCE
BNP Paribas Financial Markets's JNCE Position: Q2 2023 in Review
BNP Paribas Financial Markets sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 91,516 shares — an estimated $169K sold.
BNP Paribas Financial Markets first reported a position in JNCE in Q2 2017 and held it in 24 quarters. The position peaked at $169K in Q1 2023. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- BNP Paribas Financial Markets reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- BNP Paribas Financial Markets sold 91,516 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $169K.
- BNP Paribas Financial Markets first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 24 quarters.
- BNP Paribas Financial Markets's Jounce Therapeutics, Inc. Common Stock position peaked at $169K in Q1 2023.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2023, filed 9 Aug 2023.